Compare VISN & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VISN | BLLN |
|---|---|---|
| Founded | 1976 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.9B |
| IPO Year | N/A | 2025 |
| Metric | VISN | BLLN |
|---|---|---|
| Price | $19.43 | $92.70 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $137.83 |
| AVG Volume (30 Days) | ★ 3.9M | 222.9K |
| Earning Date | 02-26-2026 | 12-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 3.52 | N/A |
| Revenue | ★ $5,299,100,000.00 | $254,136,000.00 |
| Revenue This Year | $37.12 | $98.01 |
| Revenue Next Year | $9.59 | $36.76 |
| P/E Ratio | $5.40 | ★ N/A |
| Revenue Growth | 33.82 | ★ 254.30 |
| 52 Week Low | $2.94 | $80.00 |
| 52 Week High | $20.55 | $138.70 |
| Indicator | VISN | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 63.46 | 55.02 |
| Support Level | $17.52 | $80.65 |
| Resistance Level | $19.10 | $87.54 |
| Average True Range (ATR) | 0.86 | 5.60 |
| MACD | 0.09 | 0.97 |
| Stochastic Oscillator | 84.55 | 88.21 |
Vistance Networks Inc operates in the communications technology sector, providing solutions designed to support the delivery and management of communications services. It serves customers globally through teams involved in product development, implementation, and customer support. The company designs and develops network infrastructure and connectivity solutions focused on reliability and performance. Its offerings include intelligent networking technologies intended to support evolving communication requirements.
BillionToOne Inc is a precision diagnostics company revolutionizing molecular testing with its patented Quantitative Counting Templates (QCT) platform. This technology enables ultrasensitive, single-molecule DNA quantification, making genetic testing more accurate, affordable, and accessible. The company serves prenatal screening and oncology markets with non-invasive tests that detect fetal genetic risks and monitor cancer therapy response.